NCT01975519: A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma |
|
|
| Completed | 2a | 111 | US | TRC105 and Pazopanib, Chimeric Antibody (TRC105) to CD105, Votrient | Tracon Pharmaceuticals Inc. | Advanced Soft Tissue Sarcoma | 03/19 | 03/19 | | |
NCT01648348: Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme |
|
|
| Completed | 2 | 116 | US | Anti-Endoglin Chimeric Monoclonal Antibody TRC105, TRC105, Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar FKB238, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment | National Cancer Institute (NCI) | Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm | 05/16 | 04/17 | | |
NCT01757652: Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma |
|
|
| Recruiting | 2 | 32 | US | anti-endoglin monoclonal antibody TRC105, TRC105, pharmacological study, pharmacological studies, laboratory biomarker analysis, quality-of-life assessment, quality of life assessment | National Cancer Institute (NCI) | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor | 01/00 | | | |
